Pfizer plans offering to pare Zoetis stake
Drugmaker Pfizer Inc. plans to try to sell its controlling stake in its former animal health business, Zoetis Inc., through a voluntary stock exchange with Pfizer shareholders. Full story
Correction: Pfizer-Study Halted story
In a story May 20 about Pfizer Inc. halting a cancer drug study, The Associated Press erroneously reported the uses of two of the drugmaker's existing cancer medicines. Bosulif is approved for use in certain patients with chronic myelogenous leukemia and Inlyta is for advanced kidney cancer. Full story
Pain Therapeutics, Durect fall on Remoxy review
Shares of Pain Therapeutics Inc. and Durect Corp. tumbled Friday after their partner Pfizer Inc. said it may not pursue further development of Remoxy, an experimental pain drug that has been plagued with delays in regulatory approval. Full story
Bashful men can buy the little blue pill online
Men who are bashful about needing help in the bedroom no longer have to go to the drugstore to buy that little blue pill. Full story
Pfizer 1Q profit up, but drugmaker cuts outlook
Pfizer Inc.'s first-quarter net income rose 53 percent despite falling sales, mainly because the world's second-largest drugmaker took big charges a year ago. Pfizer's results fell short of Wall Street's expectations, and the company lowered its profit and sales forecasts for the year, blaming sudde Full story
On the Call: Pfizer CEO Ian Read
During a conference call to discuss drugmaker Pfizer Inc.'s first-quarter results, analysts asked Pfizer management about the chances they will split the New York company in two: an "innovative core" business handling Pfizer's newer medicines and development of future drugs, and a "value business" s Full story
Sponsored Links
Articles
Video
Lower-cost Lipitor alternatives may come soon
The cholesterol-lowering drug Lipitor has generated $106 billion for its manufacturer Pfizer over the past decade. But at the end of this month, Pfizer's patent expires and lower cost generic alternatives will go on the market. NBC’s Robert Bazell has more.
advertisement | ad info
Related Photos
Jansen, senior vice president of Vaccine Research and Early Development at Pfizer Inc, poses in her lab at Pfizer headquarters in Pearl River
Kathrin Jansen, senior vice president of Vaccine Research and Early Development at Pfizer Inc, poses for a portrait in one of her labs at Pfizer headquarters in Pearl River, New York, April 19, 2013. REUTERS/Carlo Allegri
People walk past the Pfizer Inc. headquarters in New York in this file photo
People walk past the Pfizer Inc. headquarters in New York, in this January 31, 2013 file photo. Pfizer Inc reported lower-than-expected quarterly earnings and revenue April 30, 2013, and the largest U.S. drugmaker trimmed its full-year profit outlook, sending shares down 5 percent in premarket tradi
People walk past the Pfizer Inc. headquarters in New York
People walk past the Pfizer Inc. headquarters in New York, January 31, 2013. REUTERS/Brendan McDermid
